Ritter Pharmaceuticals, Inc.

55 articles with Ritter Pharmaceuticals, Inc.

• 

  Clinical Catch-Up: September 9-13

  9/16/2019

  Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.

• Ritter Pharma Raises $23 Million To Fund Initiation Of Its Phase III Clinical Program In Lactose Intolerance

  10/3/2017

• Ritter Pharma Prices $23,000,000 Public Offering

  9/29/2017

• Ritter Pharma Announces Phase III Plans After Its End Of Phase II Meeting With FDA On RP-G28 For Lactose Intolerance

  8/18/2017

• Ritter Pharma Reports Second Quarter 2017 Financial Results And Provides Business Update

  8/7/2017

• Ritter Pharma Reports Further Analysis From Its Phase IIb/III Trial Results Demonstrating Significant Reductions In Lactose Intolerance Symptoms

  8/4/2017

• Ritter Pharma Reports First Quarter 2017 Financial Results And Provides Business Updates

  5/9/2017

• Ritter Pharma Announces Issuance Of New Patents For Its Lactose Intolerance Treatment, RP-G28, And Provides An Update On Its Path Forward Into Phase III

  5/3/2017

• FDA Digests Ritter Pharma's Phase II Microbiome Data

  4/13/2017

• Tiny SoCal Pharma Ritter Pharma Hails A Mid-Stage Victory After Changing The Primary Endpoint And Recalculating Data Of Lactose Intolerance Drug

  3/29/2017

• Ritter Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Business Update

  2/27/2017

• Ritter Pharmaceuticals, Inc. Announces Collaboration With University of British Columbia To Explore Development Of Microbiome Therapeutics In Environmental Enteropathy

  2/14/2017

• Ritter Pharmaceuticals, Inc. To Ring Today's Nasdaq Stock Market Closing Bell To Kick-off Lactose Intolerance Awareness Month

  1/31/2017

• Ritter Pharmaceuticals, Inc. Release: Company Announces Collaboration With University of Nebraska To Explore Development Of Microbiome Therapeutics In Metabolic Syndrome

  1/23/2017

• Ritter Pharmaceuticals, Inc. Appoints William Merino, Ph.D., To Its Board Of Directors

  1/17/2017

• Ritter Pharmaceuticals, Inc. Phase 2a Lactose Intolerance Clinical Trial Microbiome Data, Published In PNAS

  1/4/2017

• Ritter Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results And Provides Business Update

  11/7/2016

• Ritter Pharmaceuticals, Inc. Prices $5,000,000 Public Offering Of Common Stock

  10/26/2016

• Ritter Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock

  10/26/2016

• Ritter Pharmaceuticals, Inc. Concludes Last Patient Visit Of Its Phase 2b/3 Clinical Trial Of RP-G28 For The Treatment Of Lactose Intolerance

  10/18/2016